News
PCVX
47.46
+0.36%
0.17
Did Vaxcyte’s (PCVX) First-in-Human Strep Vaccine Trial Just Reframe Its Pipeline Ambitions?
Simply Wall St · 23h ago
S&P 500 Futures Fall In Premarket Trading; Super Micro Computer, XPO Lag
Dow Jones · 3d ago
Weekly Report: what happened at PCVX last week (0601-0605)?
Weekly Report · 5d ago
Vaxcyte (PCVX) Valuation Check As VAX A1 Begins Phase 1 Group A Strep Trial
Simply Wall St · 5d ago
Does Vaxcyte’s First-in-Human Group A Strep Trial Reshape The Bull Case For Vaxcyte (PCVX)?
Simply Wall St · 06/04 22:25
Vaxcyte COO Jim Wassil disposes of common shares worth $111,467.81
PUBT · 06/03 20:59
Analysts Offer Insights on Healthcare Companies: Repligen (RGEN), Vaxcyte (PCVX) and BeOne Medicines (ONC)
TipRanks · 06/03 18:00
Vaxcyte (PCVX) Has a New Rating from Mizuho Securities
TipRanks · 06/03 00:16
Vaxcyte doses first participant in VAX-A1 study
TipRanks · 06/02 20:28
Vaxcyte publishes investor presentation highlighting broad-spectrum pneumococcal vaccine pipeline lead VAX-31
PUBT · 06/02 20:17
VAXCYTE - EXPECTS TOPLINE DATA FROM VAX-A1 PHASE 1 STUDY IN H2 2027
Reuters · 06/02 20:05
Weekly Report: what happened at PCVX last week (0525-0529)?
Weekly Report · 06/01 09:20
Assessing Vaxcyte (PCVX) Valuation After Mixed Short And Long Term Share Price Moves
Simply Wall St · 05/29 14:06
S&P 500 Futures Climb In Premarket Trading; MDA Space, ViaSat Lead
Dow Jones · 05/26 11:30
Top 3 Health Care Stocks You'll Regret Missing In May
Benzinga · 05/26 10:08
Weekly Report: what happened at PCVX last week (0518-0522)?
Weekly Report · 05/25 09:20
Analysts Offer Insights on Healthcare Companies: Vaxcyte (PCVX) and BioMarin Pharmaceutical (BMRN)
TipRanks · 05/21 13:50
Why Vaxcyte (PCVX) Is Down 9.7% After Steeper Q1 Losses And Accelerated R&D Spending
Simply Wall St · 05/20 18:31
Weekly Report: what happened at PCVX last week (0511-0515)?
Weekly Report · 05/18 09:20
Notable Tuesday Option Activity: UNH, MDB, PCVX
NASDAQ · 05/12 19:28
More
Webull provides a variety of real-time PCVX stock news. You can receive the latest news about Vaxcyte, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PCVX
Vaxcyte, Inc. is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company's pipeline includes VAX-31, VAX-24 and VAX-XL. VAX-31, a 31-valent PCV candidate being evaluated in the OPUS Phase III adult clinical program and in a Phase II infant clinical program, is being developed for the prevention of IPD and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-XL leverages the Company’s carrier-sparing, site-specific conjugation technology. It is re-engineering the way highly complex vaccines are made through XpressCF, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella.